Skip to main content

Table 1 Baseline characteristics of the SQTI and normal QT groups

From: Long-term prognosis of short QT interval in Korean patients: a multicenter retrospective cohort study

  SQTI group (n = 34) Normal QT group (n = 136) P
Demographics
 Age (year) 23.5 (21.0–30.5) 23.5 (21.0–31.0)  > 0.999
 Male 31 (91.2) 124 (91.2)  > 0.999
 Family history of SCA 1 (2.9) 0 (0.0) 0.200
 Height (cm) 173.0 (170.0–176.8) 173.0 (168.0–177.0) 0.698
 Weight (kg) 66.2 (61.1–72.0) 69.5 (60.0–78.8) 0.155
 Systolic BP (mmHg) 124.0 (113.3–129.0) 122.0 (113.3–134.0) 0.537
 Diastolic BP (mmHg) 71.0 (66.0–78.0) 76.0 (67.3–83.0) 0.056
 ICD implantation 1 (2.9) 0 (0.0) 0.200
Medications
 Digoxin 2 (5.9) 1 (0.7) 0.041
 β-blocker 3 (8.8) 7 (5.1) 0.415
 Calcium channel blocker 5 (14.7) 7 (5.1) 0.052
 RASi 3 (8.8) 6 (4.4) 0.304
 Antiarrhythmic drug 2 (5.9) 2 (1.5) 0.129
Amiodarone 1 (2.9) 1 (0.7)  
Flecainide 1 (2.9) 1 (0.7)  
 Diuretics 3 (8.8) 7 (5.1) 0.415
 Lipid lowering agent 1 (2.9) 2 (1.5) 0.560
 Antiplatelet 1 (2.9) 3 (2.2) 0.800
 Anticoagulant 1 (2.9) 5 (3.7) 0.835
Symptoms
 Loss of consciousness 3 (8.8) 4 (2.9) 0.144
 Palpitations 4 (11.8) 3 (2.2) 0.030
 Chest pain 3 (8.8) 8 (5.9) 0.461
ECG characteristics
 Heart rate (/min) 52.0 (47.0–58.0) 70.0 (62.3–84.0)  < 0.001
 PR interval (ms) 160.0 (146.0–175.5) 152.0 (137.5–168.0) 0.061
 QT interval (ms) 361.0 (335.0–375.5) 380.0 (358.0–400.0) 0.001
 QTc (ms) 334.0 (330.3–337.0) 416.0 (396.3–436.8)  < 0.001
 QT dispersion (ms) 44.0 (28.0–73.0) 20.0 (12.0–35.0)  < 0.001
 JT interval (ms) 262.0 (245.0–279.0) 200.0 (169.0–224.0)  < 0.001
 U wave 4 (11.8) 0 (0) a
 Biphasic T wave 1 (2.9) 0 (0) a
 Early repolarization 25 (73.5) 14 (10.3)  < 0.001
 Tall T waves 20 (58.8) 10 (7.4)  < 0.001
 PVC 2 (5.8) 2 (1.5) 0.179
 SVT 2 (5.8) 2 (1.5) 0.179
Follow-up period (year) 4.9 (2.0–7.8) 3.8 (3.8–4.2) 0.318
  1. The results are presented as median (interquartile range) for continuous data and as frequency (percentage) for categorical data
  2. BP blood pressure, ICD implantable cardioverter-defibrillator, RASi renin angiotensin system inhibitor, PVC premature ventricular contraction, SQTI short QT interval, SVT supraventricular tachycardia
  3. aStatistical comparison could not be performed because the number of patients was small